Our results indicate that routine administration of G-CSF given from day +7 onward to patients receiving auto-SCT for myeloma results in faster engraftment than a deferred dose schedule, and also shortens the duration of severe neutropenia. This evidence concerns the gene CSF3 and plasma cell myeloma.